Evidence-based Medicine Pioneers
This article was originally published in RPM Report
Executive Summary
Evidence-based medicine has been the next big thing in pharma for over a decade -- always seemingly just on the verge of becoming a central force in the determination of the commercial success of new products. Is the field now mature enough to move to center stage. Some recent rhetoric from Pfizer makes it seem that way.
You may also be interested in...
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.
Drug Selection for the Masses
The Agency for Healthcare Research & Quality recently started translating evidence-based ratings of drugs into language consumers can use. The consumer guides are supposed to stimulate better discussions between patients and doctors about drug therapy. Can they drive therapeutic substitution as well?
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.